Juvenile Idiopathic Arthritis
Conditions
Keywords
methotrexate, Juvenile Idiopathic Arthritis
Brief summary
This study will integrate Pharmacogenomics and Pharmacometrics, to explore an effective concentration of MTXPGn for JIA pediatric patients, and set up a Population Pharmacokinetics model to provide reference for individual administration on JIA pediatric patients.
Detailed description
In order to find out The critical reasons for individual variances in MTX of JIA pediatric patients and quantize the influence of these factors, based on early research, this study will integrate Pharmacogenomics and Pharmacometrics, to explore an effective concentration of MTXPGn for JIA pediatric patients, and set up a Population Pharmacokinetics model to provide reference for individual administration on JIA pediatric patients.
Interventions
OTHERtherapeutic drug monitoring
dose of methotrexate can be adjusted by therapeutic drug monitoring.
Sponsors
Guangzhou Women and Children's Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Pediatric patients with Juvenile Idiopathic Arthritis * 7.5-10mg/m2 per week per dose of methotrexate * all patients have been treated with methotrexate at least for 3 months
Exclusion criteria
* co-treated other drugs which can interact with methotrexate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genotypes as measured by polymerase chain reaction-restriction fragment length polymorphism | 3 months | genotype are collected from hospital system. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentration as measured by liquid chromatography mass spectrometry | 3 months | concentration of methotrexate are collected from hospital system |
Countries
China
Contacts
Primary ContactXiaolan Mo, master
Backup ContactPing Zeng, master
Outcome results
None listed